North America leads the global acute myeloid leukemia treatment market because of advanced healthcare infrastructure, high R&D investments, and a growing prevalence of AML. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, driving market growth. The AML treatment market was valued at approximately USD 3.201 billion in 2024 and is projected to...